<DOC>
	<DOCNO>NCT00761189</DOCNO>
	<brief_summary>The purpose study evaluate efficacy paliperidone extended-release ( ER ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>PaliperidoNe Extended-Release ER Dosing Clinical Response Acute Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-centric ( conducted one center ) , prospective ( study follow participant forward time ) , single arm , non-comparative study paliperidone Extended Release ( ER ) participant schizophrenia . The total study duration approximately 104 week per participant . The study consist follow part : Screening ( , 14 day study commences Day 1 ) ; acute Treatment phase ( single-oral dose paliperidone 12 week , dose range 3 12 milligram ) ; Extension phase 1 ( 12 week ) Maintenance treatment follow additional Extension phase 2 long-term maintenance treatment . Efficacy participant primarily evaluate Clinical Global Impression-Improvement ( CGI-I ) scale score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants Clinical Global ImpressionSeverity ( CGIS ) score great equal 4 point ( moderately ill ) Screening Childbearing potential woman consent consistent use acceptable contraception ( oral contraceptive , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) Participants capable willing fill questionnaire Participants compliant selfmedication receive consistent help support Have schizophrenia diagnosis Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) Participants past history neuroleptic malignant syndrome ( NMS ) Participants Treatment Resistance history fail properly treat two kind antipsychotic agent ( least 4 week therapeutic dose administration ) Participants severe ( pathologic iatrogenic ) gastrointestinal stenosis participant swallow drug whole ( The study drug must chew , divide , melt grind impact study drug release profile . ) Participants expose study drug within one month screen Participants significant risk include suicide aggressive behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Paliperidone</keyword>
	<keyword>R076477</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>